2025-10-24 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided information, presented in a clear and concise format suitable for a report:

## JNJ Stock Analysis

**Ticker:** JNJ
**Company:** Johnson & Johnson (A multinational corporation that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.)

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 47.70%
*   **VOO Cumulative Return:** 99.09%
*   **Absolute Performance Gap:** -48.3% (JNJ underperformed VOO by 48.3% over the period)
*   **Relative Performance Gap:** 21.0 (JNJ is currently positioned in the lower end of its historical relative performance range against VOO).  This suggests the underperformance is significant relative to its own past fluctuations.

#### Alpha, Beta Analysis

| Year       | CAGR    | MDD    | Alpha  | Beta  | Cap(B) |
| :--------- | :------ | :----- | :----- | :---- | :----- |
| 2015-2017  | 26.0%   | 76.3%  | -2.0%  | -0.1  | 337.5  |
| 2016-2018  | 15.0%   | 10.5%  | -1.0%  | 0.1   | 311.8  |
| 2017-2019  | 20.0%   | 71.5%  | -2.0%  | 0.4   | 352.4  |
| 2018-2020  | 19.0%   | 79.3%  | -4.0%  | 0.4   | 380.2  |
| 2019-2021  | 33.0%   | 79.3%  | -13.0% | 0.5   | 413.3  |
| 2020-2022  | 9.0%    | 79.7%  | 9.0%   | 0.4   | 426.7  |
| 2021-2023  | -19.0%  | 79.7%  | -20.0% | 0.3   | 378.6  |
| 2022-2024  | -32.0%  | 79.7%  | -53.0% | 0.3   | 349.4  |
| 2023-2025  | 19.0%   | 79.6%  | -45.0% | 0.1   | 463.5  |

**Analysis:**

*   The data suggests periods of both positive and negative alpha (outperformance/underperformance relative to the market).  Recent years show significant negative alpha, indicating substantial underperformance.
*   Beta values are generally low, indicating JNJ is less volatile than the overall market (S&P 500).
*   MDD (Maximum Drawdown) is consistently high, suggesting significant potential for losses during market downturns despite the lower beta.
*   Cap(B) = market capitalization

### 2. Recent Price Action

*   **Current Price:** 191.88
*   **Last Market Price:** 192.47, **Previous Close:** 192.94, **Change:** -0.24
*   **5-Day Moving Average:** 192.42
*   **20-Day Moving Average:** 187.72
*   **60-Day Moving Average:** 179.31

**Analysis:** The price is slightly below the 5-day moving average but above the 20-day and 60-day moving averages, indicating a short-term pullback within an overall upward trend (based on the longer-term averages). The recent price change of -0.24 is not significant enough to suggest a major volatility event.

### 3. Market Risk Indicator and Indicators

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 77.22 (Overbought)
*   **PPO:** 0.0346 (Positive, indicating upward momentum)
*   **Hybrid Signal:** "cash\_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00)"
*   **Recent (20-day) Relative Performance Change:** -1.7 (Negative, indicating short-term decline in relative performance).
*   **Expected Return (%):** -78.1 (Significantly negative expected return compared to the S&P 500 over a 2+ year investment horizon).

**Analysis:** The MRI suggests a favorable investment environment. The RSI indicates the stock may be overbought and due for a correction. PPO confirms the upward trend. The hybrid signal suggests a buy with a small allocation, aligning with the high MRI. The negative recent relative performance change suggests caution. The significantly negative expected return is a major red flag, suggesting the model projects JNJ will substantially underperform the S&P 500.

### 4. Recent News & Significant Events

*   **Positive:** Focus on growth in H2 2025 driven by higher royalties, analyst upgrades on J&J.
*   **Neutral:** Appointment to the board of directors. Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference.
*   **Negative:** Concerns about Tylenol-maker Kenvue's stock performance and FDA decisions. GCC $1.25+ Bn Catheter Market Growth Trends and Forecast to 2033 Featuring Johnson & Johnson.

**Analysis:** The news is mixed. While there are positive signals regarding growth and analyst sentiment, concerns around a subsidiary (Kenvue) and the negative expected return warrant caution.

### 4-2) Analyst Opinions

*   **Consensus:** Buy (Mean Rating: 2.17)
*   **Target Price:** Average: $198.47, High: $225.00, Low: $155.00
*   **Rating Changes:** No information available regarding recent changes.

**Analysis:**  Analysts generally have a positive outlook on JNJ with a "Buy" consensus. The average target price suggests some upside potential from the current price.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue     |
| :--------- | :--- | :---------- |
| 2025-10-22 | 2.14 | 23.99 B$    |
| 2025-07-24 | 2.3  | 23.74 B$    |
| 2025-04-23 | 4.57 | 21.89 B$    |
| 2024-10-23 | 1.12 | 22.47 B$    |
| 2025-10-22 | 1.12 | 22.47 B$    |

**Analysis:**

*   Revenue is generally increasing. EPS shows more volatility. The most recent EPS (2.14) is lower than the previous quarter (2.3) but significantly higher than the same quarter last year (1.12).

### 6. Financial Information

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-06-30 | $23.74B  | 67.87%        |
| 2025-03-31 | $21.89B  | 66.40%        |
| 2024-12-31 | $22.52B  | 68.35%        |
| 2024-09-30 | $22.47B  | 69.01%        |
| 2024-06-30 | $22.45B  | 69.40%        |

| Quarter    | Equity    | ROE     |
| :--------- | :-------- | :------ |
| 2025-06-30 | $78.47B  | 7.06%   |
| 2025-03-31 | $78.11B  | 14.08%  |
| 2024-12-31 | $71.49B  | 4.80%   |
| 2024-09-30 | $70.16B  | 3.84%   |
| 2024-06-30 | $71.54B  | 6.55%   |

**Analysis:**

*   Revenue shows an upward trend. Profit margins are consistently high. Equity is increasing. ROE (Return on Equity) is volatile but generally positive.

### 7. Overall Assessment

JNJ presents a mixed picture.  While it's a stable, large-cap company with high profit margins and a "Buy" rating from analysts, several factors raise concerns:

*   **Significant Underperformance:** JNJ has significantly underperformed the S&P 500, and the model projects this underperformance to continue.
*   **Overbought Condition:** The RSI suggests the stock may be overbought and due for a correction.
*   **Kenvue Concerns:** The news regarding Kenvue, a subsidiary, adds uncertainty.
*   **Inconsistent EPS:** EPS has been volatile
*   **High Drawdown:** MDD is consistently high

**Conclusion:**

While JNJ's MRI score suggests a safe investment environment and analysts have a positive outlook, the underperformance relative to the S&P 500 and the negative expected return are significant warning signs.  Investors should carefully consider these factors before making an investment decision. The current price action suggests a short-term pullback, which might present a better entry point if the long-term outlook improves. However, the data indicates that there are external factors that can affect investment decisions. More research into the reasons behind the projected underperformance and the Kenvue situation is warranted.
